New hepatitis b drug shows promise in first human tests
NCT ID NCT07595159
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-phase trial tested an experimental drug called BW-20507 in 32 people. First, healthy volunteers received a single dose to check safety. Then, people with chronic hepatitis B received multiple doses to see how the drug behaves in the body and whether it fights the virus. The main goal was safety, not effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BW-20507 (an experimental drug given as an injection)
- What this could lead to
- If successful, this could point toward a new treatment option for chronic hepatitis B, potentially helping control the virus long-term.
- What could go wrong
- This is a very early Phase 1 trial with only 32 participants, focused on safety. It is too small and early to know if the drug works or is safe for wider use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Argo Investigative Site
Beijing, Beijing Municipality, 100050, China
-
Argo Investigative Site
Chongqing, Chongqing Municipality, 404000, China
-
Argo Investigative Site
Guanzhou, Guangdong, 510700, China
-
Argo Investigative Site
Xuzhou, Jiangsu, 221000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data